W J Hrushesky1, G A Bjarnason. 1. Albany Medical College, Stratton Veterans Administration Medical Center, NY 12208.
Abstract
PURPOSE AND DESIGN: To review briefly the growing body of published data about circadian variation in cytotoxic drug metabolism and tissue sensitivity to chemotherapeutic agents. The suggestion that toxicity may be reduced and anticancer efficacy improved by administering antineoplastic agents at carefully selected times of the day was assessed. RESULTS AND CONCLUSION: The medical literature describing molecular, cellular, and organismic time-keeping mechanisms, as well as circadian rhythms, in cytokinetic, pharmacokinetic, and pharmacodynamic parameters relevant to cancer chemotherapy, which support the predictable rhythmic relationship between dose and effect that occurs during each day, were reviewed. Advantages for optimal circadian scheduling have been demonstrated for diminishing side effects and increasing maximal safe dose-intensity of drugs of diverse class. The use of the predictable circadian relationship of dose and response provides another increment of progress in the treatment of cancer patients.
PURPOSE AND DESIGN: To review briefly the growing body of published data about circadian variation in cytotoxic drug metabolism and tissue sensitivity to chemotherapeutic agents. The suggestion that toxicity may be reduced and anticancer efficacy improved by administering antineoplastic agents at carefully selected times of the day was assessed. RESULTS AND CONCLUSION: The medical literature describing molecular, cellular, and organismic time-keeping mechanisms, as well as circadian rhythms, in cytokinetic, pharmacokinetic, and pharmacodynamic parameters relevant to cancer chemotherapy, which support the predictable rhythmic relationship between dose and effect that occurs during each day, were reviewed. Advantages for optimal circadian scheduling have been demonstrated for diminishing side effects and increasing maximal safe dose-intensity of drugs of diverse class. The use of the predictable circadian relationship of dose and response provides another increment of progress in the treatment of cancerpatients.
Authors: Yanyan Yang; Ogun Adebali; Gang Wu; Christopher P Selby; Yi-Ying Chiou; Naim Rashid; Jinchuan Hu; John B Hogenesch; Aziz Sancar Journal: Proc Natl Acad Sci U S A Date: 2018-05-07 Impact factor: 11.205
Authors: Wendy Landier; Lindsey Hageman; Yanjun Chen; Nancy Kornegay; William E Evans; Bruce C Bostrom; Jacqueline Casillas; David S Dickens; Anne L Angiolillo; Glen Lew; Kelly W Maloney; Leo Mascarenhas; A Kim Ritchey; Amanda M Termuhlen; William L Carroll; Mary V Relling; F Lennie Wong; Smita Bhatia Journal: J Clin Oncol Date: 2017-03-24 Impact factor: 44.544
Authors: Swann Arp Adams; James R Hebert; Susan Bolick-Aldrich; Virginie G Daguise; Catishia M Mosley; Mary V Modayil; Sondra H Berger; Jane Teas; Michael Mitas; Joan E Cunningham; Susan E Steck; James Burch; William M Butler; Marie-Josephe D Horner; Heather M Brandt Journal: J S C Med Assoc Date: 2006-08
Authors: John Griniatsos; Othon P Michail; Stamatios Theocharis; Antonios Arvelakis; Ioannis Papaconstantinou; Evangelos Felekouras; Emmanouel Pikoulis; Ioannis Karavokyros; Chris Bakoyiannis; George Marinos; John Bramis; Panayiotis O Michail Journal: World J Gastroenterol Date: 2006-04-07 Impact factor: 5.742